ClinicalTrials.gg
CompletedNCT05448443ATOHSUpdated Feb 27, 2025

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome

A Phase 2 interventional study of AD981 and Placebo in Obesity Hypoventilation Syndrome (OHS), sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Istituto Auxologico Italiano · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, double blind, placebo-controlled, cross-over, phase II, single center efficacy study of AD981 in patients with obesity hypoventilation syndrome documented by polysomnography (PSG) and transcutaneous, overnight measurement of CO2 (PtcCO2).

02

Conditions studied

  • Obesity Hypoventilation Syndrome (OHS)
03

In context

Obesity Hypoventilation Syndrome

73 studies on the registry are indexed under Obesity Hypoventilation Syndrome; 10 are open to participants now.

This study's enrollment of 15 is below the median of 40 across 42 interventional studies indexed under Obesity Hypoventilation Syndrome.

Browse Obesity Hypoventilation Syndrome studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 203 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able to understand the nature of the study and sign the
  • > 35 kg/m2 and presence of nocturnal hypoventilation
  • Previous surgical treatment for OSA is allowed if ≥ 1 year prior to enrollment
  • If in treatment, CPAP or BPAP or mandibular advancement device or positional therapy intolerance or poor compliance

Exclusion criteria

Exclusion Criteria:

  • Narcolepsy, craniofacial malformation, renal failure, hepatic disease, schizophrenia, schizoaffective disorder or bipolar disorder, cognitive dysfunction, severe neurological disorder, pheochromocytoma, adrenocortical insufficiency, hyperchloremic acidosis.
  • Respiratory (, ILD, oxygen therapy) or cardiac (Heart Failure, Atrial fibrillation, established severe peripheral arterial disease) disease or hypertension requiring more than 3 medications for control
  • Cardiomyopathies, heart malformation or structural heart alterations, severe rhythm disorders, established coronary heart disease or other cardiac conditions, which could determine sudden death
  • Attempted suicide or suicidal ideation
  • Drugs of abuse or substance use disorder
  • A significant illness or infection requiring medical treatment in the past 30 days.
  • Untreated narrow angle glaucoma.
  • Women who are pregnant or nursing.
  • Treatment with strong cytochrome P450 3A4 () inhibitors, or monoamine oxidase inhibitors (MAOI) or linezolid within 14 days of the start of treatment, allergies to sulfonamides.
  • Diabetes with unstable glucose control in the past 15 days.
  • > 500 mg/day of Aspirin
  • Low sodium or potassium.
  • Any condition that in the investigator's opinion would present an unreasonable risk to the participant.
  • History of using oral or nasal devices (such as mandibular advancement devices) for the treatment of OSA may enroll as long as the devices are not used during participation in the study for at least 2 weeks prior to study begin.
  • History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used during participation in the study.
  • Use of another agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
  • Patient currently receiving: MAOIs, Serotonin and Norepinephrine Reuptake Inhibitors, Norepinephrine Reuptake Inhibitors, Lithium, Tricyclic antidepressants, strong CYP2D6 inhibitors, other strong inhibitors cytochrome P450, thiazides diuretics, benzodiazepines, opioids, drugs with cardiac -interval prolonging effects, drugs known to lower seizure threshold, amphetamines, antiepileptics, modafinil or armodafinil, beta2 agonists, antipsychotics, pseudoephedrine, phenylephrine, oxymetazoline, drugs for Parkinson's, Alzheimer's, Huntington's, Amyotrophic Lateral Sclerosis, or drugs for other neurodegenerative diseases, more than 500 mg/day of Aspirin or salicylates, sodium Phosphate.
  • Known to study drugs
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    AD981

    AD981

    Drug: AD981

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • DrugAD981

    Oral administration of AD981 in the morning and before sleep for 14 days

  • OtherPlacebo

    Oral administration of placebo in the morning and before sleep for 14 days

06

What researchers measure

Primary outcomes

  1. Nocturnal transcutaneous CO2 pressure (PtcCO2)

    Time frame: From baseline to the last day of treatment (14 days after the start of each treatment period)

Secondary outcomes

  1. Proportion of participants without nocturnal hypoventilation

    Time frame: From baseline to the last day of treatment (14 days after the start of each treatment period)

  2. Apnea-Hypopnea Index (AHI)

    Time frame: From baseline to the last day of treatment (14 days after the start of each treatment period)

07

Study locations

1 site
  • Istituto Auxologico Italiano,Ospedale San Luca
    Milano, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in May 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 7, 2022
StartActual
Jun 21, 2022
Primary completionActual
May 8, 2024
CompletionActual
May 8, 2024
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05448443
Collaborators
Apnimed Inc., VIS Ethic Research Srl, University of Florence, STM Pharma PRO srl
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Jun 21, 2022
Primary completion
May 8, 2024
Completion
May 8, 2024
Last update
Feb 27, 2025

Study contacts

Elisa Perger, MD
principal investigator · Istituto Auxologico Italiano

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion